Company
Captor Therapeutics
- Biotech
- Headquarters:
- Wroclaw, Poland
- Offices:
- Allschwil, Switzerland
Description
Captor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and autoimmune disorders for biopharmaceutical and clinical research customers.
Related
Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…
BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
Jazz PharmaceuticalsJazz Pharmaceuticals develops and commercializes medicines for people with rare diseases, focusing on therapies for epilepsies, cancers and…
SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
Laigo BioLaigo Bio develops SureTACs, bispecific molecules that bind membrane targets and membrane E3 ligases to drive ubiquitin-mediated, lysosomal…
GlycanosticsGlycanostics develops non-invasive liquid biopsy cancer diagnostics, building antibody-coated magnetic particle tests that detect glycan…
Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
RS ResearchRS Research develops targeted oncology therapies and smart nanomedicines using the Sagitta® polymer-drug conjugate platform for targeted…